Becton Dickinson and Company (BDX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

BDX scores 67 out of 100 (letter grade C+; verdict: Roarable Hold — Upper Neutral / Watch for Breakout). The five pillars are:

• Fundamental Cash Engine: 10 / 20. this pillar reflects ROIC of 4.9% and an FCF yield of 2.13%. Both figures are modest, which limits the cash-generation case for a higher score and implies that the current valuation (P/E TTM 32.2) relies heavily on expectations rather than cash returns on invested capital.
• Whale / 13F Flow: 18 / 20. this is the strongest pillar, described as institutional accumulation and options positioning. The source does not itemize the underlying 13F filings, so the size and timing of this accumulation cannot be verified here.
• Insider Conviction: 12 / 20. this reflects SEC Form 4 and Congressional PTR cluster flow at a moderate level.
• Macro Regime Fit: 13 / 20. beta is 1.06, indicating market-like volatility with a sector sensitivity component. An investor should expect the stock to move roughly in line with the broader market.
• Forensic Balance Sheet: 14 / 20. Altman Z is 2.22, Piotroski F is 8 of 9, and Debt/Equity is 0.67. Per the same rating, these metrics indicate a sound but not pristine balance sheet, with the Altman Z-Score in a range that does not signal distress.

Taken together, the rating points to a stock whose institutional support and balance sheet strength are offset by thin cash returns and a premium valuation. The verdict's "Watch for Breakout" language implies that the rating is awaiting a catalyst for re-rating, rather than signaling an immediate directional call. The price of 198.34 sits near the top of the 52-week range of $127.59 to $200.47 (per market data), so upside from current levels depends on continued execution and sentiment improvement. This is an analytical framing, not personalized advice.

Becton Dickinson and Company is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry (per the company profile). The company reported FY 2025 revenue of $21.84B, indicating a large-scale operation. Gross margin is 45.4% per market data.

Revenue grew from $19.37B (FY 2023) to $21.84B (FY 2025), while net income moved from $1.48B to $1.68B, with a peak of $1.71B in FY 2024. Market data shows an operating margin of 11.8% and a net margin of 7.7%. ROIC is 4.9%, Altman Z-Score is 2.22, and Piotroski F-Score is 8 of 9. Debt stood at $16.92B in FY 2025 against cash of $740.0M, and the Debt/Equity ratio is 0.67 per the rating's forensic data.

• 🐂 Primary Bull Case: Institutional whale accumulation (18/20) and a Piotroski F-Score of 8 of 9 support the thesis despite a 52-week high near $200.47. With Fundamental Cash Engine at 10/20 (ROIC 4.9%, FCF yield 2.13%) and Institutional Whale Flow at 18/20, sustained execution supports upside toward the top of the $127.59 – $200.47 52-week range.
• 🐻 Primary Bear Case: A 4.9% ROIC and 2.13% FCF yield leave a 32.2x trailing P/E resting on expectations rather than cash returns. Investors must weigh 32.2x trailing P/E and 21.8x EV/EBITDA against 11.8% operating margins and a 1.06 macro beta if sector demand softens.

The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies and no sector correlation links. The sector (Health Care) and industry (Medical/Dental Instruments) are identified in the profile, but the source provides no mapping of supplier, customer, or peer relationships. Investors should treat second-order effects as unmapped by this dataset.

• Key Question #1: What drove the gap between 5.4% revenue growth and a 34.3% earnings decline, and is that gap structural or one-time?
• Key Question #2: What is the FY 2025 EPS and free cash flow, which the financials table leaves unreported?
• Key Question #3: What is the company's supplier and customer dependency map, given the Butterfly graph shows none?